Mereo BioPharma FY 2025 cash and cash equivalents fall 41.28% to USD 40.99 million

Reuters03-19 20:31
Mereo BioPharma FY 2025 cash and cash equivalents fall 41.28% to USD 40.99 million
  • Mereo published a full-year earnings release, reporting revenue of USD 0.5 million and net loss of USD 41.88 million.
  • R&D expense fell 14.95% to USD 17.77 million, driven by lower alvelestat and etigilimab spending after completion of Phase 3 preparation activities in 2024, partly offset by higher setrusumab costs under a manufacturing and supply agreement with Ultragenyx.
  • G&A expense decreased 12.96% to USD 23.01 million, mainly due to a lower annual cash bonus accrual and reduced professional fees.
  • Cash and cash equivalents declined 41.28% to USD 40.99 million, which Mereo said is expected to fund operating expenses and capital expenditure requirements into mid-2027.
  • Business updates included ongoing additional analyses from the Phase 3 Orbit and Cosmic setrusumab studies after missing primary fracture-rate endpoints, completion of site feasibility work for a global Phase 3 alvelestat trial, and āshibio’s plan to initiate a Phase 2 study of vantictumab in osteopetrosis in the second half of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mereo BioPharma Group plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190830PRIMZONEFULLFEED9675004) on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment